Targeting ALK: Precision Medicine

Anaplastic Lymphoma Kinase (ALK) is an oncogene frequently found as a fusions in non-small cell lung cancer (NSCLC), as EML4-ALK. Precision medicine uses therapeutic agents that target specific mutations, such as those found in ALK-positive NSCLC patients. Discover the latest research on Targeting ALK here.

September 5, 2020
Review
Open Access

Novel Multitarget Therapies for Lung Cancer and Respiratory Disease

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Masako YumuraYoshihiro Nishimura
September 13, 2020
Open Access

Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells

Scientific Reports
Georg WolfstetterRuth H Palmer
August 28, 2020
Case Report
Open Access

Successful use of extracorporeal membrane oxygenation for airway-obstructing lung adenocarcinoma

Thoracic Cancer
Shinsuke KitazawaYukio Sato
September 15, 2020
Case Report
Open Access

Novel ALK Fusion, PPFIBP1-ALK , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib

JCO Precision Oncology
Arjan GowerAndrew Eugene Hendifar
September 4, 2020

Research progress in immune checkpoint inhibitors in the treatment of oncogene- driven advanced non- small cell lung cancer

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Yuxin LiJianhua Chen
September 15, 2020

CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib

JCO Precision Oncology
Michael OffinAlexander Drilon
September 16, 2020
Open Access

A clinico-epidemiological, pathological, and molecular study of lung cancer in Northwestern India

Journal of Cancer Research and Therapeutics
H S DarlingRahul Sud
September 12, 2020
Review
Open Access

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer

Cancer Immunology, Immunotherapy : CII
H AdderleyC R Lindsay
September 2, 2020

Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients

Anti-cancer Drugs
Maximilian Johannes HochmairArschang Valipour
August 26, 2020

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer

Zhongguo fei ai za zhi = Chinese journal of lung cancer
Yuke TianJuan Li
September 13, 2020
Open Access

Collision Tumor Composed of an Inflammatory Myofibroblastic Tumor and Adenocarcinoma of the Colon: a Rare Entity

Journal of Gastrointestinal and Liver Diseases : JGLD
Chiara CornacchiaMarco Filauro

Sign up to follow this feed and discover related papers.

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2020 Meta ULC. All rights reserved
/feed-previews/targeting-alk-precision-medicine/c48cfa46-6be8-4509-a864-f6cc18b7903d